TAIPEI, March 17, 2025 /PRNewswire/ -- Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in combination with current medications for ...
CUPERTINO, Calif., Dec. 16, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in ...
About Microbio Co. Ltd. Microbio Co., Ltd. engages in the research, development, manufacture, and sale of new drugs and healthcare products. The company also supplies raw materials to pharmaceutical ...
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, ...
TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the ...
Leo Pharma is paying $40 million upfront and $530 million in biobucks to license a midstage experimental eczema and asthma drug. The therapy, FB825, has been developed by Oneness Biotech and Microbio ...
Brisbane medtech scale-up Microbio has developed a game-changing pathogen test to help identify “a silent killer” that is notoriously difficult to predict, diagnose and treat, as the signs and ...
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer ...
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback